A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma
Author:
David S. Siegel,Thomas Martin,Michael Wang,Ravi Vij,Andrzej J. Jakubowiak,Sagar Lonial,Suzanne Trudel,Vishal Kukreti,Nizar Bahlis,Melissa Alsina,Asher Chanan-Khan,Francis Buadi,Frederic J. Reu,George Somlo,Jeffrey Zonder,Kevin Song,A. Keith Stewart et al.
Copyright © 2012 American Society of Hematology